Cooperation agreement between Polpharma Biologics and the University of Warsaw
Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward buil…
Polpharma Biologics – The Polish biosimilar powerhouse
“Other companies come to us and want CDMO work in the biosimilar space because we know what we’re doing, but our goal…
Polpharma Biologics integrates Dutch based subsidiary, Bioceros, to offer the complete spectrum of services from discovery to commercial supply.
Gdansk, Poland and Utrecht, The Netherlands 13th July 2020. In 2016, Polpharma Biologics acquired Dutch based Biocero…
On Demand Webinar: Looking to develop a high quality, high titer manufacturing cell line?
We have developed our SPOT™ technology alongside our proprietary CHO cell line to increase the cell line specific pro…
All hands on deck! We all fight with COVID-19
The current situation caused by COVID-19 concerns us all. We had decided to help because we care. That’s why we have…
Bioceros develops monoclonal antibodies as a division of Polpharma Biologics Group
Dr. Louis Boon, Chief Scientific Officer of Bioceros (division of Polpharma Biologics Group), talked about Bioceros C…
First subjects in ph III study with PB006 (proposed Biosimilar to Natalizumab) have been randomized.
Our phase III clinical trial (PB006-03-01) entered into the stage when first patients were treated with study medicat…
Polpharma Biologics announces global commercialization deal for biosimilar natalizumab, a key multiple sclerosis medicine
Polpharma Biologics today announces that it has entered a global commercialization agreement with Sandoz AG for a nat…
32nd International Symposium on Preparative and Process Chromatography in Baltimore
We participated in the 32nd International Symposium on Preparative and Process Chromatography in Baltimore.
Launching of the 4th edition of the Career Laboratory!
We are starting recruitment for the 4th edition of our Career Laboratory internship program.